Generic losartan to hit U.S. shelves

The FDA has approved losartan potassium tablets, a generic version of Merk’s Cozaar/Hyzaar, in 25 mg, 50 mg and 100 mg strength, for marketing in the U.S.

Losartan potassium is an angiotensin II receptor antagonist indicated to treat hypertension that can be used alone or in combination with other antihypertensive agents, including diuretics.

According to IMS Health, losartan potassium tablets saw U.S. sales reach an estimated $940 million for the 12 months, which ended June 30.

Actavis Group of Hafnarfjörour, Iceland, and Mylan Pharmaceuticals of Pittsburgh will commercially sell the generic drug in the U.S.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.